

INDEX

Note: Page numbers in *italics* indicate figures; page numbers followed by t refer to tables.

- α -adrenergic blockade
 - in sexual dysfunction, 106t
 - vasoconstriction with, 124
- Abdominal discomfort
 - clozapine and, 66t
 - quetiapine and, 80t
 - risperidone and, 84t
- Abilify. *See also Aripiprazole.*
 - adverse effects of, 60-61, 61t
 - clinical trials in, 59
 - dopamine effects, 59
 - dosing information for, 56-57t, 59
 - efficacy, 59
 - history and mechanism of action, 58
 - in management of acute psychosis, 170-171t
 - pharmacokinetics, 59
 - SGAD therapy with, 37t
- Abnormal gait, with olanzapine therapy, 74-75t
- Abnormal Involuntary Movement Scale (AIMS), evaluation of antipsychotic
 - side effects in, 48, 49
- Absorption, factors affecting, 227-228
- Acarbose (Precose), antidiabetic mechanism of, 164-165t
- Accidental injury
 - comparative incidence of, in SGAD therapy, 99t
 - with olanzapine therapy, 74-75t
 - with ziprasidone, 88t
- Actos. *See Pioglitazone.*
 - antidiabetic mechanism of, 164-165t
- Acute psychosis. *See Psychiatric emergency.*
- Adherence to drug therapy. *See Noncompliance.*
- Adolescents
 - diagnosing considerations in, 213
 - treatment of psychosis in, 214-216
- Affect, in symptomatology of schizophrenia, 13
- Age, in epidemiology of schizophrenia, 14t
- Aggression
 - in symptomatology of schizophrenia, 25
 - management of, 172
 - medications linked to, 172t
- Agitation
 - in rebound phenomenon, 63
 - in treatment with conventional antipsychotics, 125
 - with aripiprazole, 61t
 - with clozapine, 66t

- Agitation (*continued*)
 with paliperidone ER, 78t
 with risperidone, 84t
- Agranulocytosis, with clozapine, 65
- AIMS, See *Abnormal Involuntary Movement Scale*.
- Akathisia
 comparative incidence of, in SGAD therapy, 99t, 103
 with aripiprazole, 61t
 with clozapine, 66t
 with high-dose antipsychotic therapy, 172
 with long-acting risperidone, 193-194
 with olanzapine therapy, 74-75t
 with ziprasidone, 88t
- AKT1, in vulnerability for schizophrenia, 21t
- Alcohol
 abuse, with schizophrenia, 220-222
 association with aggressive behavior, 172t
- Alcoholism, in predisposition to QTc prolongation, 110
- Aliphatics
 chemical structure of, 118-119
 in phenothiazine subtyping, 115
- Alogia
 in differential diagnosis, 28t
 in negative symptomatology of schizophrenia, 25t
- Alpha-1 receptor, adverse effects with antagonism of, 122t
- Alpha-glucosidase inhibitors, antidiabetic mechanism of, 164-165t
- Altshuler, evaluation of pregnancy and antipsychotic use, 225
- Alzheimer's disease
 SGAD therapy in, 219
 psychosis with, in the elderly, 217
- Amantadine, use of, in patients on antipsychotic drugs, 155
- Amaryl. See also *Glimepiride*.
 antidiabetic mechanism of, 164-165t
- Amblyopia, with olanzapine therapy, 74-75t
- Amenorrhea
 treatment considerations in, 40-41t
 with risperidone, 85
- American Diabetes Association
 diagnostic criteria of, for type 2 diabetes, 157-158, 158t
 monitoring recommendations of
 for glucose dysregulation, 154t, 162
 for lipid profile, 163, 165
- American Psychiatric Association, treatment guidelines of, 35
- Ampakines, potential benefits of, in schizophrenia, 239
- Amphetamines
 association with aggressive behavior, 172t
 positive psychotic symptoms with, 16
- Anabolic steroids, association with aggressive behavior, 172t
- Anhedonia
 in negative symptomatology of schizophrenia, 25t
- Anhedonia (*continued*)
 in rebound phenomenon, 63
 with functional brain changes, 16t
- Anorexia, with ziprasidone, 88t
- Anticholinergic side effects
 comparative incidence of, in SGADs, 100t
 comparative, with conventional antipsychotic therapy, 122, 123t, 125-126
 in antipsychotic therapy for the elderly, 218
 susceptibility to, of elderly patients, 218
 treatment considerations in, 40-41t, 125
- Anticonvulsant medications
 association with aggressive behavior, 172t
 in management of aggression, 172
- Antipsychotic medication
 introduction of, 15
 metabolism and distribution of, 228-229
- Anxiety
 comparative incidence of, in SGAD therapy, 99t
 in assessment of psychopathology, 44t
 in symptomatology of schizophrenia, 25
 with aripiprazole, 61t
 with paliperidone ER, 78t
 with risperidone, 84t
- Anxiety disorder
 treatment of, with antipsychotic drugs, 33
 with schizophrenia, treatment of, 222-224
- Appetite disturbance, in symptomatology of schizophrenia, 185
- Arcuate, role in effect of antipsychotic drugs, 16, 17
- Aripiprazole
 adverse effects of, 60-61, 61t
 as first-line therapy, by comorbidity, 40-41t
 chemical structure of, 55
 clinical trials in, 59
 comparative efficacy of, 94-97, 96t
 comparative incidence of extrapyramidal side effects in, 98, 102, 104
 comparative side effects of, 98, 99t, 100t
 diabetic ketoacidosis in, 161
 dopamine effects, 59
 dopamine receptor affinity of, 101
 dosing information for, 56-57t, 59
 effect of, on glucose homeostasis, 162
 effect of, on QTc interval, 111
 effect on cognition by, 237
 efficacy, 59
 history and mechanism of action, 58
 in adolescents and children with schizophrenia, 214
 in combination therapy for treatment-resistant schizophrenia, 207t
 in management of acute psychosis, 170-171t
 in SGAD therapy, 37t
 in the elderly, 218, 220

- Aripiprazole (*continued*)
- in treatment algorithm, 38
 - in treatment of aggressive behavior, 173
 - in treatment-resistant schizophrenia, 205
 - in young patients, 97
 - lipid changes with, 165
 - metabolism of, 230t
 - pharmacokinetics, 59
 - potential benefits of new forms of, 182
 - profiles for receptor binding, 54
 - receptor affinity of, 95t
 - relapse with, vs conventional therapy, 242
 - sedative effect, in clinical trials, 112
 - vs risperidone in prevention of relapse, 178
 - weight gain with, 150, 151, 152t
- Arthralgia
- with hepatic changes in antipsychotic therapy, 128
 - with risperidone, 84t
- Articulation impairment, with olanzapine therapy, 74-75t
- Asenapine, in new developments for treating schizophrenia, 250
- Asthma
- with aripiprazole, 61t
 - with olanzapine therapy, 74-75t
 - with quetiapine, 80t
 - with ziprasidone, 88t
- Asymmetry of frontal and occipital lobes, associated with schizophrenia, 15t
- Atropine, in hypersalivation, 68t
- Attention, in schizophrenia, 235
- Auditory symptoms, with functional brain changes, 16t
- Autoimmune disorder, in diagnosis of psychotic disorder, 30t
- Avandia. See *Rosiglitazone*.
- antidiabetic mechanism of, 164-165t
- Avolition
- in differential diagnosis, 28t
 - in negative symptomatology of schizophrenia, 25t
- Avolitional syndrome, 21
- β -adrenergic effects, in mechanism for vasoconstriction, 124
- β -blocking agents, in management of aggressive behavior, 172
- Back pain
- with olanzapine therapy, 74-75t
 - with quetiapine, 80t
 - with risperidone, 84t
- Barnes Akathisia Rating Scale (BARS), in evaluation of antipsychotic side effects, 48, 49
- BARS. See *Barnes Akathisia Rating Scale*.
- Basal ganglia
- role of, in dopaminergic receptor-deficit hypothesis, 18
 - role of, in effect of antipsychotic drugs, 16, 17
- Benzodiazepines
- association with aggressive behavior, 172t
 - in acute antipsychotic treatment, 35
 - in management of aggressive behavior, 172
 - in schizoaffective disorder, 223, 224
 - in schizophrenia with depression, 223, 224
 - with clozapine therapy, 69
- Benztropine, in hypersalivation, 68t
- Bethanechol
- in treatment of anticholinergic effects of conventional antipsychotics, 125
 - in treatment of sexual disturbance in antipsychotic therapy, 109t
- Bifeprunox, in new developments for treating schizophrenia, 250
- Biguanides, antidiabetic mechanism of, 164-165t
- Biperiden, in hypersalivation, 68t
- Bipolar disorder
- in diagnosis of psychotic disorder, 30t
 - SGAD therapy in, 222-223
 - treatment of, with antipsychotic drugs, 33
- Bizarre delusions, defined, 23t
- Bleuler, Eugene, in early characterization of schizophrenia, 14
- Blonanserin, in new developments for treating schizophrenia, 251
- Blunted affect
- in assessment of psychopathology, 47t
 - in negative symptomatology of schizophrenia, 25t
- Blurred vision, with aripiprazole, 61t
- BPRS. See *Brief Psychiatric Rating Scale*.
- Bradycardia, in predisposition to QTc prolongation, 110
- Brain activation patterns, in treatment-resistant schizophrenia, 199
- Brief Psychiatric Rating Scale (BPRS)
- in assessment of psychopathology, 43, 44-47t
 - in evaluation of SGAD effects in psychiatric emergency, 173
- Broca's area
- impact of functional changes in, 16t
 - role in effect of antipsychotic drugs, 16, 17
- Bromocriptine
- in treatment of NMS, 131-132, 132t
 - in treatment of sexual disturbance in antipsychotic therapy, 109t
- Buspirone
- in schizoaffective disorder, 224
 - in schizophrenia with depression, 224
- Butyrophenones
- as subclass of antipsychotic medication, 116, 118-119
 - chemical structure of, 118-119
 - in pregnancy/lactation, 225
- CAFE study. See *Comparison of Atypicals for First-Episode Psychosis study*.
- Calcium channel blockade, in sexual dysfunction, 106t
- Calgary Depression Rating Scale, comparison of SGAD efficacy by, 97

- Cannabis
 abuse, with schizophrenia, 220-222
 association with aggressive behavior, 172t
- Carbamazepine
 effect of, on metabolism of antipsychotic drugs, 231t
 effect on drug absorption, 228
 in schizoaffective disorder, 223
 in schizophrenia with depression, 223
- Cardiac arrhythmias, treatment considerations in, 40-41t
- Cardiac disease, in predisposition to QTc prolongation, 110
- Cardiomyopathy, with clozapine therapy, 69
- Cardiorespiratory arrest, with clozapine therapy, 69
- Cardiovascular effects
 comparative, with conventional antipsychotic therapy, 122, 123t
 with clozapine, 69
 with olanzapine, 73
 with quetiapine, 80
 with risperidone, 83
 with ziprasidone, 89
- Carpenter, characterization of schizophrenia by, 21
- Cataracts, with quetiapine, 81
- Catatonic type, in categorization of schizophrenia, 26
- Catechol-*O*-methyltransferase val108/158met, in predicting antipsychotic efficacy, 236
- CATIE trial. See *Clinical Antipsychotic Trials for Interventions Effectiveness*.
- Caudate nucleus, role in effect of antipsychotic drugs, 16, 17
- CBT. See *Cognitive behavior therapy*.
- Central adipose tissue, metabolic activity in, 147
- Central nervous system
 measurement of, in patient evaluation, 15
 neurotransmitter levels of, 15
- Cerebellar atrophy, associated with schizophrenia, 15t
- CGI. See *Clinical Global Impression*.
- Chest pain
 with olanzapine therapy, 74-75t
 with risperidone, 84t
- Children. See *Adolescents*.
- Children's Psychiatric Rating Scale, PANSS in evaluation of treatment, 216
- Chills, with hepatic changes in antipsychotic therapy, 128
- Chlorpromazine
 adverse effects with, 123t
 anticholinergic effects of, 125
 chemical structure of, 118-119
 contraindicated with ziprasidone, 232
 dopamine receptor affinity of, 101
 dosing guidelines for, 120-121t
 effect on cognition by, 237
 for acute agitation, 168
- Chlorpromazine (*continued*)
 history of, 33, 115
 in conventional antipsychotic therapy, 36t
 in determination dosage equivalence, 116, 214
 in therapy for treatment-resistant schizophrenia, 198
 incidence of type 2 diabetes with, 157
 orthostatic hypotension with, 124
 weight gain with, 149, 151
- Cholestyramine, effect on drug absorption, 227
- Cholinergic antagonism, in sexual dysfunction, 106t
- Cholinesterase inhibitors, potential benefits of, in schizophrenia, 239
- Cigarette smoking, effect of, on metabolism of antipsychotic drugs, 231t
- Cimetidine, effect of, on metabolism of antipsychotic drugs, 231t
- Cingulate gyrus, impact of functional changes in, 16t
- Circumstantiality, in thought disorder, 24t
- Cisapride, effect of, on metabolism of antipsychotic drugs, 231t
- Clanging, in thought disorder, 24t
- Classification of conventional medications, 116
- Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE)
 antipsychotic medication change in, 179
 economic comparisons in, 246
 extrapyramidal side effects in, 98
 extrapyramidal symptoms in, 94
 in evaluation of antipsychotic medications, 94
 incidence of type 2 diabetes in, 158
 lipid changes in, 163
 on clozapine in treatment-resistant schizophrenia, 201
 on comparative efficacy and tolerability in SGADs, 93
 sexual dysfunction in, 108
 weight changes in, 149, 153, 153t
- Clinical Global Impression (CGI), in assessment of treatment response, 43
- Clinical presentation, 20-26
- Clonidine, in hypersalivation, 68t
- Clozapine
 adverse effects of, 65-71, 66-67t
 as first-line therapy, by comorbidity, 40-41t
 benefit of, in risk for suicide, 174
 chemical structure of, 55
 clinical trials in, 59
 comparative incidence of extrapyramidal side effects in, 98, 102, 104
 comparative sexual function with, 106
 comparative side effects of, 98, 99t, 100t
 diabetic ketoacidosis in, 161
 dopamine receptor affinity of, 101
 dosing information for, 56-57t, 63, 63t
 drug interactions with, 230, 232t
 effect on cognition by, 237
 efficacy, 62
 history, 61-62

- Clozapine (*continued*)
- in adolescents and children with schizophrenia, 214, 215-216
 - incidence of type 2 diabetes with, 157
 - increased risk for, 159, 161, 162
 - mechanism for, 158
 - in combination therapy for treatment-resistant schizophrenia, 206, 207t
 - in schizoaffective disorder, 222, 223
 - in schizophrenia with depression, 223
 - in schizophrenia with substance abuse, 221
 - in SGAD therapy, 37t
 - in the elderly, 218, 219, 220
 - in therapy for treatment-resistant schizophrenia, 62, 198, 199, 200, 201, 202-203t
 - in treatment algorithm, 38
 - in treatment of aggressive behavior, 173
 - in treatment-resistant schizophrenia, 197
 - introduction of, 34
 - lipid changes with, 163, 165
 - mechanism of action, 62
 - metabolic syndrome with, 146
 - metabolism of, 230t
 - pharmacokinetics, 64
 - potential benefits of new forms of, 182
 - potential cost benefits of, 246
 - profiles for receptor binding, 54
 - rebound phenomenon with, 63
 - receptor affinity of, 95t
 - serotonin selectivity of, 19
 - vs chlorpromazine, in Kane, 62
 - vs risperidone in treatment-resistant schizophrenia, 201
 - weight gain with, 149, 150, 151
- Clozaril. See also *Clozapine*.
- adverse effects of, 65-71, 66-67t
 - clinical trials in, 59
 - dosing information for, 56-57t, 63, 63t
 - efficacy, 62
 - history, 61-62
 - in SGAD therapy, 37t
 - in therapy for treatment-resistant schizophrenia, 198
 - mechanism of action, 62
 - pharmacokinetics, 64
 - rebound phenomenon with, 63
- CNS. See *Central nervous system*.
- Cocaine
- abuse, with schizophrenia, 220-222
 - association with aggressive behavior, 172t
 - positive psychotic symptoms with, 16
- Cognitive behavior therapy (CBT)
- in combination therapy for treatment-resistant schizophrenia, 208
 - in psychosocial rehabilitation, 42
- Cognitive deficit, with schizophrenia, 235
- Cognitive disturbance, in treatment with conventional antipsychotics, 125
- Cognitive remediation (CR), in psychosocial rehabilitation, 42
- Cognitive symptoms, 13, 22, 23t
- Combination therapy
- in the elderly, 217-220
 - in treatment-resistant schizophrenia, 205-208
- Comparison of Atypicals for First-Episode Psychosis (CAFE) study, 97
- Compliance, as factors in relapse, 241
- Conceptual disorganization, in assessment of psychopathology, 44t
- Concreteness, in thought disorder, 24t
- Confusion, with clozapine, 66t
- Congenital long QT syndrome, in predisposition to QTc prolongation, 110
- Constipation
- comparative incidence of, in SGAD therapy, 99t
 - with aripiprazole, 61t
 - with clozapine, 66t
 - with long-acting risperidone, 193-194
 - with olanzapine therapy, 74-75t
 - with quetiapine, 80t
 - with risperidone, 84t
 - with ziprasidone, 88t
- Consumption of a large meal, in predisposition to QTc prolongation, 110
- Conventional therapy. See also *specific drugs*.
- adverse effects of, 121-132
 - available agents for, 36t
 - chemical structure of, 115, 118-119
 - depot preparations of, 190-191, 191t
 - effect on cognition by, 237
 - efficacy and dosing, 116-117, 120-121t
 - history of, 115
 - in adolescents and children with schizophrenia, 214
 - incidence of extrapyramidal effects with, vs SGAD therapy, 98, 102
 - increased risk of suicide with, 174
 - limitations of, 33
 - mechanisms of action, 115
 - overview of, 34-35
 - pharmacokinetics, 117
 - vs SGAD therapy in treatment adherence, 242-243
 - vs SGADs in treatment adherence, 242-243
 - vs SGADs, 34
- Cortical atrophy
- in schizophrenia, 15t
 - in treatment-resistant schizophrenia, 199
- Cost-effectiveness. See also *Economics*.
- of SGADs vs conventional therapy, 35
- Cough
- with aripiprazole, 61t
 - with olanzapine therapy, 74-75t
 - with risperidone, 84t
 - with ziprasidone, 88t

CR. See *Cognitive remediation*.

Creatine phosphokinase, in Levenson's diagnostic criteria for NMS, 131t

Cyproheptadine, in treatment of sexual disturbance in antipsychotic therapy, 109t

D-amino-acid-oxidase activator, in vulnerability for schizophrenia, 21t

DAO, in vulnerability for schizophrenia, 21t

DAOA, in vulnerability for schizophrenia, 21t

Deafness, in diagnosis of psychotic disorder, 30t

Deficit syndrome, 21, 25, 25t

Definition of schizophrenia, 20

Delirium, in diagnosis of psychotic disorder, 30t

Delusions

- in differential diagnosis, 28t
- in symptomatology of schizophrenia, 13
- of influence, 23t
- types of, 22, 23t
- with functional brain changes, 16t

Deméncé précoce, in historical description of mental illness, 14

Dementia

- in diagnosis of psychotic disorder, 30t
- treatment of, with antipsychotic drugs, 33

Dementia praecox, in historical description of mental illness, 14, 222

Depersonalization, defined, 23t

Depression

- in assessment of psychopathology, 45t
- treatment of, with antipsychotic drugs, 33
- with schizophrenia, SGAD therapy in, 222-223

Derealization, defined, 23t

Dermatologic effects, of conventional psychotic therapy, 127

Desmopressin, in clozapine therapy, 71

Diabeta. See *Glyburide*.

- antidiabetic mechanism of, 164-165t

Diabetes

- classification of, 157-158, 158t
- management of, 162, 164-165t
- mechanism of action, 158, 160
- risk of, in schizophrenia, 156
- in untreated patients, 159-161
- treatment considerations in, 40-41t

Diabetic ketoacidosis

- with antipsychotic drugs, 161
- management of, 162-163

Diagnostic and Statistical Manual of Mental Disorders, 4th edition

- definition of schizophrenia in, 26
- rating scales used by, 48

Diagnostic criteria, 26-27, 28-29

Diarrhea

- with clozapine, 67t
- with ziprasidone, 88t

Diazepam, for acute agitation, 168

Dibenzodiazepines, as subclass of antipsychotic medication, 116, 118-119

Dibenzoxazepines, chemical structure of, 118-119

Diencephalic gliosis, associated abnormalities of, in schizophrenia, 15t

Dihydroergotamine, with clozapine therapy, 69

Dihydroindolones

- as subclass of antipsychotic medication, 116, 118-119
- chemical structure of, 118-119

Diltiazem, effect of, on metabolism of antipsychotic drugs, 231t

Diphenylbutylpiperidines

- as subclass of antipsychotic medication, 116, 118-119
- chemical structure of, 118-119

DISC1, in vulnerability for schizophrenia, 21t

Disorganized behavior

- in differential diagnosis, 28t
- in symptomatology of schizophrenia, 13

Disorganized speech

- in differential diagnosis, 28t
- in symptomatology of schizophrenia, 13

Disorganized type, in categorization of schizophrenia, 26

Disorientation

- in assessment of psychopathology, 47t
- in treatment with conventional antipsychotics, 125

Dizziness

- comparative incidence of, in SGAD therapy, 99t
- with clozapine, 66t
- with olanzapine therapy, 74-75t
- with paliperidone ER, 78t
- with quetiapine, 80t
- with ziprasidone, 88t

Docusate, in treatment of anticholinergic effects of conventional antipsychotics, 125

Dofetilide, contraindicated with ziprasidone, 89

Dopamine receptor antagonism

- adverse effects of, 122t
- effect of, on satiety, 148
- in conventional therapy, 115
- in mechanism of action, conventional therapy, 53
- in sexual dysfunction, 106t

Dopamine transmission, role of, in schizophrenia, 19

Dopamine transmitter system, dysfunction of, in schizophrenia, 18

Dopaminergic hyperactivity, impact on glucose metabolism, 18

Dopaminergic hypoactivity, impact on glucose metabolism, 18

Dopaminergic receptor-deficit hypothesis, 18-19, 249

Dopaminergic system, in etiology of schizophrenia, 16-19, 17, 18t

Droperidol, contraindicated with ziprasidone, 232

Drowsiness, with clozapine, 66t

Drug absorption, factors affecting, 227-228

Drug interactions, 227-233

Drug intoxication, in diagnosis of psychotic disorder, 30t

- Dry mouth
 comparative incidence of, in SGAD therapy, 99t
 with clozapine, 66t
 with long-acting risperidone, 193-194
 with olanzapine therapy, 74-75t
 with quetiapine, 80t
 with ziprasidone, 88t
- Dry skin, with risperidone, 84t
- D-serine, potential benefits of, in schizophrenia, 239
- DTNBP1, in vulnerability for schizophrenia, 21t
- Duration of symptoms, in differential diagnosis, 28t
- Duration of untreated psychosis, impact on prognosis, 96
- Dysbindin, in vulnerability for schizophrenia, 21t
- Dyspepsia
 comparative incidence of, in SGAD therapy, 99t
 with aripiprazole, 61t
 with long-acting risperidone, 193-194
 with olanzapine therapy, 74-75t
 with paliperidone ER, 78t
 with quetiapine, 80t
 with risperidone, 84t
 with ziprasidone, 88t
- Early-onset schizophrenia, 213
- Echymosis, with olanzapine therapy, 74-75t
- Echolalia, in thought disorder, 24t
- Economics, impact of schizophrenia on, 244-245, 245t
- Elderly patients, antipsychotic treatment of, 216-220
- Electroconvulsive therapy, in treatment-resistant schizophrenia, 205
- Electrolyte imbalance, in diagnosis of psychotic disorder, 30t
- Emotional withdrawal, in assessment of psychopathology, 44t
- Employment, issues in schizophrenia, 243
- Endocrine disturbances
 in diagnosis of psychotic disorder, 30t
 with antipsychotic therapy, 129
- Enuresis, in antipsychotic-treated children, 215
- Ephedrine, in clozapine therapy, 71
- Epidemiologic Catchment Area Study, schizophrenia in the elderly in, 216-217
- Epidemiology, 13-14, 14t
- Epilepsy, in diagnosis of psychotic disorder, 30t
- Epileptogenic effects, with antipsychotic therapy, 128
- Ergotomatic delusions, defined, 23t
- Erythromycin, effect of, on metabolism of antipsychotic drugs, 231t
- Etiology of schizophrenia, 16
- Excitement, in assessment of psychopathology, 47t
- Executive function, in schizophrenia, 235
- Extrapyramidal pathway, role in effect of antipsychotic drugs, 16, 17
- Extrapyramidal symptoms
 comparative incidence of, in SGAD therapy, 99t, 100t
- Extrapyramidal symptoms (*continued*)
 in CATIE trial, 94
 in schizophrenia with substance abuse, 220-222
 in sexual dysfunction, 106t
 noncompliance due to, 242
 SGAD vs conventional therapy in children, 215
 susceptibility to, of elderly patients, 218
 treatment considerations in, 40-41t
 with haloperidol therapy, 168
 with paliperidone ER, 77, 78t
 with risperidone, 84t
 with SGAD vs conventional therapy, 98
 with ziprasidone, 88t
- Extremity pain, with olanzapine therapy, 74-75t
- Family education, in psychosocial rehabilitation, 42
- Farampator
 in new developments for treating schizophrenia, 251
 potential benefits of, in schizophrenia, 239
- Fatigue
 with clozapine, 67t
 with hepatic changes in antipsychotic therapy, 128
 with long-acting risperidone, 193-194
- Fazaclo. See also *Clozapine*.
 in SGAD therapy, 37t
- FDA. See *Food and Drug Administration*.
- Female gender, in predisposition to QTc prolongation, 110
- Fenfluramine, use of, in patients on antipsychotic drugs, 155
- Fever
 comparative incidence of, in SGAD therapy, 99t
 in Levenson's diagnostic criteria for NMS, 131t
 in treatment with conventional antipsychotics, 125
 with clozapine, 66t
 with hepatic changes in antipsychotic therapy, 128
 with olanzapine therapy, 74-75t
 with quetiapine, 80t
 with risperidone, 84t
- FGA. See *First-generation antipsychotic (drug)*.
- First-generation antipsychotic drug. See also *Conventional therapy*.
 in treatment algorithm, 38
 vs second-generation agents, 96-97
- Fluency, in schizophrenia, 235
- Fluid imbalance, in diagnosis of psychotic disorder, 30t
- Fluoroquinolones, effect of, on metabolism of antipsychotic drugs, 231t
- Fluoxetine
 effect of, on metabolism of antipsychotic drugs, 231t
 in schizoaffective disorder, 223
 in schizophrenia with depression, 223
- Fluphenazine
 adverse effects with, 123t

- Fluphenazine (*continued*)
 chemical structure of, 118-119
 depot preparations of, 119-120
 dopamine receptor affinity of, 101
 dosing guidelines for, 120-121t
 for long-acting antipsychotic therapy, 190, 191t
 in conventional antipsychotic therapy, 36t
 in treatment algorithm, 38
 introduced for antipsychotic use, 33
 metabolism, 229-233
 relapse with, 242
 vs risperidone in treatment-resistant schizophrenia, 201
 weight gain with, 151
- Fluvoxamine
 effect of, on metabolism of antipsychotic drugs, 231t
 in combination therapy for treatment-resistant schizophrenia, 207t
 in schizoaffective disorder, 223
 in schizophrenia with depression, 223
- fMRI. See *Functional magnetic resonance imaging*.
- Food and Drug Administration (FDA)
 guidelines for clozapine (Clozaril) in resistant disease, 198, 202-203t
 recommendations for clozapine administration, 65
- Frontal cortex, role of, in dopaminergic receptor-deficit hypothesis, 18
- Functional abnormalities, 15, 15t, 16t
- Functional magnetic resonance imaging (fMRI), in characterization of
 brain abnormality, 14
- Fungal dermatitis, with ziprasidone, 88
- Future direction of therapy, 249-252
- Galactorrhea, with risperidone, 107
- Galantamine, potential benefits of, in schizophrenia, 239
- GAF. See *Global Assessment of Function scale*.
- GAS. See *Global Assessment Scale*.
- Gastrointestinal disturbance, with hepatic changes in antipsychotic
 therapy, 128
- Gatifloxacin, contraindicated with ziprasidone, 232
- Genes involved in schizophrenia, 20-21
- Genetic polymorphism, interaction of, with antipsychotic therapy, 236
- Genetic predisposition, potential role in psychotic disease, 19-20, 20-21t
- Geodon. See also *Ziprasidone*.
 adverse effects, 87-90, 88t
 dosing information for, 56-57t
 efficacy, 86-87
 history, 86
 in management of acute psychosis, 170-171t
 in SGAD therapy, 37
 mechanism of action, 86
 pharmacokinetics, 87
- Geriatrics. See *Elderly patients*.
- Glaucoma, with conventional antipsychotic therapy, 126
- Glimepiride (Amaryl), antidiabetic mechanism of, 164-165t
- Glipizide (Glucotrol), antidiabetic mechanism of, 164-165t
- Global Assessment of Function (GAF) scale, vs GAS in evaluation of
 function, 48
- Global Assessment Scale (GAS)
 example of, 50-51t
 in evaluation of function, 48
- Glucophage. See *Metformin*.
 antidiabetic mechanism of, 164-165t
- Glucophage XR. See *Metformin*.
 antidiabetic mechanism of, 164-165t
- Glucose dysregulation, in psychotic patients, 156-163
- Glucose metabolism
 comparative changes of, in SGADs, 100t
 role of, in dopaminergic receptor-deficit hypothesis, 18
- Glucotrol. See *Glipizide*
 antidiabetic mechanism of, 164-165t.
- Glucovance. See *Glyburide and metformin*.
 antidiabetic mechanism of, 164-165t
- Glutamate release, role of, in schizophrenia, 19
- Glutamate subtype receptor, role of, in schizophrenia, 18-19
- Glutamate transmitter system, dysfunction of, in schizophrenia, 18
- Glutamatergic transmission, role in cognitive processes, 238
- Glyburide (Diabeta), antidiabetic mechanism of, 164-165t
- Glyburide and metformin (Glucovance), antidiabetic mechanism of,
 164-165t
- Glycine, potential benefits of, in schizophrenia, 239
- Glycopyrrolate, in hypersalivation, 68t
- Glyset. See *Miglitol*.
 antidiabetic mechanism of, 164-165t
- Grandiose delusions, defined, 23t
 in assessment of psychopathology, 45
- Grapefruit, effect of, on metabolism of antipsychotic drugs, 231t
- Guilt feelings, in assessment of psychopathology, 45t
- Gynecomastia, with risperidone, 107
- Haldol. See also *Haloperidol*.
 in conventional antipsychotic therapy, 36t
- Hallucinations
 in assessment of psychopathology, 46t
 in differential diagnosis, 28t
 in symptomatology of schizophrenia, 13, 22
 in treatment with conventional antipsychotics, 125
- Halofantrine, contraindicated with ziprasidone, 232
- Haloperidol
 adverse effects with, 123t
 chemical structure of, 118-119
 chemical structure of, 55
 comparative incidence of extrapyramidal side effects in, 98, 102, 104
 depot preparations of, 119-120

Haloperidol (*continued*)

- dopamine receptor affinity of, 101
 - dosing guidelines for, 120-121t
 - effect of, on metabolism of antipsychotic drugs, 231t
 - effect of, on QTc interval, 111
 - effect on cognition by, 237
 - extrapyramidal symptoms in, 168
 - for acute agitation, 168
 - for long-acting antipsychotic therapy, 190, 191t
 - in adolescents and children with schizophrenia, 214
 - in CATIE trial, 94
 - in conventional antipsychotic therapy, 36t
 - in long-term maintenance therapy, 178
 - in pregnancy/lactation, 225
 - in schizophrenia with substance abuse, 221
 - in treatment algorithm, 38
 - in treatment of aggressive behavior, 173
 - introduced for antipsychotic use, 33
 - metabolism of, 229-233, 230t
 - of SGADs, 95t
 - potential cost benefits of, 246
 - profiles for receptor binding, 54
 - remission rates with, 185
 - surgically implantable, long-acting, preclinical studies of, 195
 - vs olanzapine, 72
 - vs risperidone in prevention of relapse, 178
 - vs risperidone in treatment-resistant schizophrenia, 201
 - vs ziprasidone, 87
 - weight gain with, 150, 151
- ## Headache
- comparative incidence of, in SGAD therapy, 99t
 - with aripiprazole, 61t
 - with clozapine, 66t
 - with paliperidone ER, 78t
 - with quetiapine, 80t
 - with risperidone, 84t
- ## Heart failure, in predisposition to QTc prolongation, 110
- ## Hecker, in early characterization of mental illness, 14
- ## Hematologic side effects
- of clozapine, 65
 - of conventional psychotic therapy, 126
- ## Hepatic disease, in diagnosis of psychotic disorder, 30t
- ## Hepatic effects, of conventional psychotic therapy, 127
- ## Hepatic metabolism
- of paliperidone ER, 76
 - of risperidone, 83
- ## Hippocampus
- impact of functional changes in, 16t
 - role in effect of antipsychotic drugs, 16, 17

Histamine receptor

- adverse effects with antagonism of, 122t
 - influence of, in weight gain, 140, 150
- ## Historical perspective, 13
- ## Homovanillic acid (HVA), role of, in dopaminergic receptor-deficit hypothesis, 18
- ## Hostility
- in assessment of psychopathology, 46t
 - in symptomatology of schizophrenia, 25
- ## Huntington's chorea, in diagnosis of psychotic disorder, 30t
- ## HVA. See *Homovanillic acid*.
- ## Hypercapnia, in diagnosis of psychotic disorder, 30t
- ## Hyperglycemia, in predisposition to QTc prolongation, 110
- ## Hyperkinesia, with paliperidone ER, 78t
- ## Hyperlipidemia
- in schizophrenic patients, 163
 - management of, 163, 165
 - treatment considerations in, 40-41t
 - with antipsychotic therapy, 163
- ## Hypersalivation
- in antipsychotic-treated children, 215
 - with clozapine, 68
 - treatments for, 68t
- ## Hypertension
- with clozapine, 66t
 - with olanzapine therapy, 74-75t
- ## Hyperthyroidism, in diagnosis of psychotic disorder, 30t
- ## Hypertonia, with olanzapine therapy, 74-75t
- ## Hypertriglyceridemia, treatment considerations in, 40-41t
- ## Hypnagogic hallucinations, in diagnosis of psychotic disorder, 30t
- ## Hypnopompic hallucinations, in diagnosis of psychotic disorder, 30t
- ## Hypoadrenocorticism, in diagnosis of psychotic disorder, 30t
- ## Hypocalcemia, in predisposition to QTc prolongation, 110
- ## Hypoglycemia, in diagnosis of psychotic disorder, 30t
- ## Hypokalemia, in predisposition to QTc prolongation, 110
- ## Hypokinesia, with clozapine, 66t
- ## Hypomagnesemia, in predisposition to QTc prolongation, 110
- ## Hypotension
- comparative incidence of, in SGAD therapy, 99t
 - with clozapine, 66t
- ## Hypothalamus, role in effect of antipsychotic drugs, 16, 17
- ## Hypothyroidism
- in diagnosis of psychotic disorder, 30t
 - in predisposition to QTc prolongation, 110
 - with quetiapine, 79
- ## Hypoxia, in diagnosis of psychotic disorder, 30t
-
- ## Ideas of reference, defined, 23t
- ## Iloperidone, in new developments for treating schizophrenia, 250
- ## Increased appetite, with olanzapine therapy, 74-75t

- Insomnia
 in rebound phenomenon, 63
 with aripiprazole, 61t
 with clozapine, 67t
 with olanzapine therapy, 74-75t
 with paliperidone ER, 78t
 with risperidone, 84t
- Invega. See also *Paliperidone ER*.
 adverse effects, 77, 78t
 dosing, 76
 efficacy, 75-76
 history, 75
 in SGAD therapy, 37t
 mechanism of action, 75
 pharmacokinetics, 76
- Itraconazole, effect of, on metabolism of antipsychotic drugs, 231t
- Jervell and Lange-Nielsen syndrome, in predisposition to QTc prolongation, 110
- Joint pain, with olanzapine therapy, 74-75t
- Kahlbaum, in early characterization of mental illness, 14
- Ketamine
 role of, in modeling schizophrenia, 18
 potential benefits of, in schizophrenia, 239
- Ketoconazole, effect of, on metabolism of antipsychotic drugs, 231t
- Kraepelin
 characterization of schizophrenia by, 21, 222
 in early characterization of mental illness, 14
- Kussmaul's respiration, 161
- Lack of insight, defined, 23t
- Lactation, management of schizophrenia during, 224-225
- Lamotrigine, in combination therapy for treatment-resistant schizophrenia, 207t
- Leukopenia, with clozapine, 66t
- Lightheadedness, with aripiprazole, 61t
- Lipid abnormalities, comparative incidence of, in SGADs, 100t
- Lithium
 effect on drug absorption, 228
 in renal impairment, 233
 in schizoaffective disorder, 223
 in schizophrenia with depression, 223
- Liver disease, in predisposition to QTc prolongation, 110
- Long-acting antipsychotic drug therapy
 benefits and disadvantages of, 189-190
 SGAD vs conventional, 189, 190-191
- Long-term outcome, 241-243
- Loose association, in thought disorder, 24t
- Lorazepam, for acute agitation, 168
- Low-energy diets, in predisposition to QTc prolongation, 110
- Loxapine
 adverse effects with, 123t
 chemical structure of, 118-119
 dopamine receptor affinity of, 101
 dosing guidelines for, 120-121t
 in conventional antipsychotic therapy, 36t
- Loxitane. See also *Loxipine*.
 in conventional antipsychotic therapy, 36t
- LSD. See *Lysergic acid diethylamide*.
- Lurasidone, in new developments for treating schizophrenia, 251
- Lysergic acid diethylamide (LSD), role of, in generation of serotonin hypothesis of psychosis, 19
- Maintenance therapy, recommendations for, 177
- Major depression, in diagnosis of psychotic disorder, 30t
- Malaise
 in rebound phenomenon, 63
 with hepatic changes in antipsychotic therapy, 128
- Manic depressive psychosis, Kraepelin description of, 222
- Mannerisms, in assessment of psychopathology, 45t
- Marijuana. See *Cannabis*.
- MATRICES project, consensus building in, 236
- Medical disorder, exclusion of, in diagnosis of schizophrenia, 29t
- Mefloquine, contraindicated with ziprasidone, 232
- Meglitinides, antidiabetic mechanism of, 164-165t
- Mellaril. See also *Thioridazine*.
 in conventional antipsychotic therapy, 36t
- Memory, in schizophrenia, 235
- Menstrual irregularities
 with conventional antipsychotic therapy, 103
 with olanzapine, 107
 with risperidone, 107
- Meridia. See *Sibutramine*.
- Mesocortical
 effect of antipsychotic drugs on, 18
 role in effect of antipsychotic drugs, 16, 17
- Mesolimbic pathway
 effect of antipsychotic drugs on, 18
 role in effect of antipsychotic drugs, 16, 17
- Mesoridazine
 adverse effects with, 123t
 anticholinergic effects of, 125
 chemical structure of, 118-119
 contraindicated with ziprasidone, 232
 dosing guidelines for, 120-121t
 effect on cognition by, 237
 in conventional antipsychotic therapy, 36t
 weight gain with, 151
- Metabolic abnormalities, in predisposition to QTc prolongation, 110

Metabolic conditions, in diagnosis of psychotic disorder, 30t

Metabolic syndrome
 cardiovascular disease in, 145, 146t
 in schizophrenic patients, 146
 in treatment of anticholinergic effects of conventional antipsychotics, 125

Metamucil
 NCEP definition of, 145,
 role of antipsychotic medications in, 46

Metformin (Glucophage, Glucophage XR), antidiabetic mechanism of, 164-165t

Midriasis, in treatment with conventional antipsychotics, 125

Mifepristone, in new developments for treating schizophrenia, 250

Miglitol (Glyset), antidiabetic mechanism of, 164-165t

Migraine, in diagnosis of psychotic disorder, 30t

Mitral valve prolapse, in predisposition to QTc prolongation, 110

Moban. See also *Molindone*.
 in conventional antipsychotic therapy, 36t

Molindone, weight gain with, 151
 adverse effects with, 123t
 chemical structure of, 118-119
 dopamine receptor affinity of, 101
 dosing guidelines for, 120-121t
 in conventional antipsychotic therapy, 36t

Mood disorder
 exclusion of, in diagnosis of schizophrenia, 29t
 with schizophrenia, treatment of, 222-224

Morel, in early characterization of mental illness, 14

Motor retardation, in assessment of psychopathology, 47t

Movement, effect of antipsychotic drugs on, 18

Moxifloxacin, contraindicated with ziprasidone, 89, 232

Muscarinic receptor, adverse effects with antagonism of, 122t

Myalgia, with hepatic changes in antipsychotic therapy, 128

Myocardial infarction, in predisposition to QTc prolongation, 110

Myocardial ischemia, in predisposition to QTc prolongation, 110

Myocarditis, in predisposition to QTc prolongation, 110

Myoclonus, as warning sign in clozapine therapy, 70

Nateglinide (Starlix), antidiabetic mechanism of, 164-165t

National Cholesterol Education Program, definition of metabolic syndrome, 145, 46t

National Institutes of Mental Health
 MATRICS project of, 236
 recommendations on clozapine therapy, 63

Nausea
 comparative incidence of, in SGAD therapy, 99t
 in rebound phenomenon, 63
 with aripiprazole, 61t
 with clozapine, 66t
 with risperidone, 84t
 with ziprasidone, 88t

Navane. See also *Thiothixene*.
 in conventional antipsychotic therapy, 36t

NCEP. See *National Cholesterol Education Program*.

Nefazodone, effect of, on metabolism of antipsychotic drugs, 231t

Negative symptoms
 characterization of, 22, 25, 25t
 effect of antipsychotic drugs on, 18
 in differential diagnosis, 28t
 with functional brain changes, 16t

Neologism, in thought disorder, 24t

Neoplasm, in diagnosis of psychotic disorder, 30t

Neuregulin, in vulnerability for schizophrenia, 21t

Neuroadrenoline antagonism, effect of, on satiety, 148

Neurocognition
 deficits in schizophrenia, 235
 importance of, in treatment outcome, 236
 susceptibility to, of elderly patients, 218

Neuroleptic agents. See *Conventional therapy*.

Neuroleptic Malignant Syndrome (NMS), 130-132, 131t, 132t

Neurologic conditions, in diagnosis of psychotic disorder, 30t

Nigrostriatal tract
 effect of antipsychotic drugs on, 18
 role in effect of antipsychotic drugs, 16, 17

Nizatadine, use of, in patients on antipsychotic drugs, 155

N-methyl-D-aspartate (NMDA), role of, in schizophrenia, 18-19

NMS. See *Neuroleptic Malignant Syndrome*.

Nonadherence, treatment considerations in, 40-41t

Noncompliance
 adverse effects, as cause of, 182
 contributing factors in, 181, 181t
 improvement of, with SGADs, 182
 new formulations for, 182
 nonpharmacologic methods for improving, 183
 relapse factors in, 241

Nonpharmacologic therapy, 39, 42
 Psychosocial interaction as, 39

NRG1, in vulnerability for schizophrenia, 21t

Nucleus accumbens, role in effect of antipsychotic drugs, 16, 17

Obesity
 in predisposition to QTc prolongation, 110
 treatment considerations in, 40-41t

Olanzapine
 adverse effects of, 73, 74t
 as first-line therapy, by comorbidity, 40-41t
 chemical structure of, 55
 comparative efficacy of, 94-97, 96t
 comparative incidence of extrapyramidal side effects in, 98, 102, 104
 comparative side effects of, 98, 99t, 100t
 diabetic ketoacidosis in, 161

- Olanzapine (*continued*)
- discontinuation rates, in CATIE, 179
 - dopamine receptor affinity of, 101
 - dosing information for, 56-57t, 72
 - drug interactions with, 230, 232t
 - effect of, on QTc interval, 111
 - effect on cognition by, 237
 - efficacy, 71
 - history of, 71
 - in adolescents and children with schizophrenia, 214, 215-216
 - in CAFE study, 97
 - in CATIE trial, 94
 - in combination therapy for treatment-resistant schizophrenia, 207t
 - in first-episode schizophrenia, 97
 - in management of acute psychosis, 170-171t
 - in new developments for treating schizophrenia, 250
 - in schizophrenia with substance abuse, 221
 - in SGAD therapy, 37t
 - in the elderly, 218, 220
 - in therapy for treatment-resistant schizophrenia, 199
 - in treatment algorithm, 38
 - in treatment of aggressive behavior, 173
 - in treatment-resistant schizophrenia, 204
 - lipid changes with, 165
 - long-acting, phase 3 trials of, 195
 - mechanism of action, 71
 - metabolic syndrome with, 146
 - metabolism of, 229-233, 230t
 - pharmacokinetics, 72
 - potential benefits of new forms of, 182
 - profiles for receptor binding, 54
 - receptor affinity of, 95t
 - remission rates with, 185
 - sedative effect, in clinical trials, 112
 - vs clozapine in risk for suicide, 174
 - vs haloperidol, 71-72
 - vs risperidone in prevention of relapse, 178
 - weight gain with, 149, 150, 151, 152t
- Omeprazole, effect of, on metabolism of antipsychotic drugs, 231t
- Onset, in epidemiology of schizophrenia, 13, 14t
- Ophthalmic changes, of conventional psychotic therapy, 126
- Orap. See also *Pimozide*.
- in conventional antipsychotic therapy, 36t
- Orbitofrontal cortex, in treatment-resistant schizophrenia, 199
- Orlistat, use of, in patients on antipsychotic drugs, 155
- OROS technology, with paliperidone ER, 75, 76
- Orthostatic hypotension
- comparative incidence of, in SGADs, 100t
 - in antipsychotic therapy for the elderly, 218
 - with clozapine therapy, 69
 - with conventional therapies, 124
- Overinclusiveness, in thought disorder, 24t
- Paliperidone ER
- adverse effects, 77, 78t
 - as first-line therapy, by co-morbidity, 40-41t
 - chemical structure of, 55
 - comparative incidence of extrapyramidal side effects in, 98, 102, 104
 - comparative side effects of, 98, 99t, 100t
 - dosing, 76
 - efficacy, 75-76
 - history, 75
 - in adolescents and children with schizophrenia, 214
 - in new developments for treating schizophrenia, 250
 - in SGAD therapy, 37t
 - in treatment-resistant schizophrenia, 205
 - in young patients, 97
 - mechanism of action, 75
 - pharmacokinetics, 76
 - sedative effect, in clinical trials, 112
 - studies of, 75-76
 - weight gain with, 152t
- PANSS. See *Positive and Negative Syndrome Scale*.
- Paranoid type, in categorization of schizophrenia, 27
- Parietal cortex
- impact of functional changes in, 16t
 - role in effect of antipsychotic drugs, 16, 17
- Parkinsonian symptoms, in antipsychotic therapy for the elderly, 218
- Parkinson's disease
- in predisposition to QTc prolongation, 110
 - psychosis with, in the elderly, 217
 - SGAD therapy in, 219
 - with long-acting risperidone, 193-194
- Paroxetine
- effect of, on metabolism of antipsychotic drugs, 231t
 - in schizoaffective disorder, 223
 - in schizophrenia with depression, 223
- Pathophysiology, 14-19
- PCP. See *Phencyclidine*.
- Pentamidine, contraindicated with ziprasidone, 232
- Peripheral edema, with olanzapine therapy, 74-75t
- Periventricular nuclei, role in effect of antipsychotic drugs, 16, 17
- Perphenazine
- adverse effects with, 123t
 - chemical structure of, 118-119
 - dosing guidelines for, 120-121t
 - effect of, on metabolism of antipsychotic drugs, 231t
 - in CATIE trial, 94, 153t
 - in conventional antipsychotic therapy, 36t
 - in schizophrenia with substance abuse, 221
 - metabolism of, 229-233, 230t

- Persecutory delusions, defined, 23t
- Perseveration, in thought disorder, 24t
- Personality disorder, comparative incidence of, in SGAD therapy, 99t
- Pervasive developmental disorder
 exclusion of, in diagnosis of schizophrenia, 29t
 in diagnosis of psychotic disorder, 30t
- PET. See *Positron emission tomography*.
- Pharmacodynamics
 definition of, 227
 in the elderly, 217-220
- Pharmacokinetics
 definition of, 227
 in the elderly, 217-220
- Pharyngitis
 with olanzapine therapy, 74-75t
 with risperidone, 84t
- Phencyclidine (PCP)
 role of, in modeling schizophrenia, 18
 potential benefits of, in schizophrenia, 239
- Phenobarbital
 association with aggressive behavior, 172t
 effect of, on metabolism of antipsychotic drugs, 231t
- Phenothiazines
 as subclass of antipsychotic medication, 116, 118-119
 chemical distinctions among, 115-116, 118-119
 in pregnancy/lactation, 225
 lipid changes with, 163, 165
- Phenteramine, use of, in patients on antipsychotic drugs, 155
- Phenylpropanolamine, association with aggressive behavior, 172t
- Phenytoin
 effect of, on metabolism of antipsychotic drugs, 231t
 in prevention of seizure with clozapine therapy, 70
- Physiologic changes, in responsive vs resistant schizophrenia, 199
- Pimozide
 chemical structure of, 118-119
 contraindicated with ziprasidone, 89, 232
 dosing guidelines for, 120-121t
 in combination therapy for treatment-resistant schizophrenia, 207t
 in conventional antipsychotic therapy, 36t
- Pioglitazone (Actos), antidiabetic mechanism of, 164-165t
- Piperazines
 chemical structure of, 118-119
 in phenothiazine subtyping, 115
- Piperidines
 chemical structure of, 118-119
 in phenothiazine subtyping, 115
- Pituitary, role in effect of antipsychotic drugs, 16, 17
- Polypharmacy, in the elderly, 217-220
- Portal blood system, role in effect of antipsychotic drugs, 16, 17
- Positive and Negative Syndrome Scale (PANSS)
 comparison of SGAD efficacy by, 97
 in assessment of schizophrenia, 43, 48
 in evaluation of treatment in children, 216
- Positive symptoms, with functional brain changes, 16t
- Positron emission tomography (PET)
 in characterization of brain abnormality, 14
 role of, in dopaminergic receptor-deficit hypothesis, 18
- Postural hypotension
 comparative incidence of, in SGAD therapy, 99t
 with olanzapine therapy, 74-75t
 with quetiapine, 80t
- Posturing, in assessment of psychopathology, 45t
- Prandin. See *Repaglinide*.
 antidiabetic mechanism of, 164-165t
- Precose. See *Acarbose*.
- Prefrontal cortex
 impact of functional changes in, 16t
 role in effect of antipsychotic drugs, 16, 17
- Pregnancy, management of schizophrenia during, 224-225
- Prenatal environment, role of, in genesis of psychotic disease, 20
- Prevalence, in epidemiology of schizophrenia, 14t
- Priapism, with risperidone, 107
- Prodromal effects, of conventional antipsychotic therapy, 127
- Prodromal phase, characteristics of, 13
- Prognosis, 27
 factors affecting, 30, 30t, 241-242
 impact of therapeutic advances on, 39
- Prolactin changes
 comparative incidence of, in SGADs, 100t, 106-107
 mechanism of, in antipsychotic therapy, 103, 106, 106t
 with paliperidone ER, 76
 with risperidone, 83
- Prolactin concentrations, effect of antipsychotic drugs on, 18
- Prolixen. See also *Fluphenazine*.
 in conventional antipsychotic therapy, 36t
- Protease inhibitors, effect of, on metabolism of antipsychotic drugs, 231t
- Pruritus, with hepatic changes in antipsychotic therapy, 128
- Psychiatric emergency
 aggressive behavior in, 172-173
 management goals of, 167
 SGADs in, 169-171, 171-172t
 suicidal behavior in, 173-174, 175t
- Psychomotor symptoms, with functional brain changes, 16t
- Psychopathology, in relapse, 241
- Psychosis
 concept of disease in, 13
 effect of antipsychotic drugs on, 18
 historical perspective, 13
- Psychosocial function, in symptomatology of schizophrenia, 13

Psychosocial intervention, as nonpharmacologic therapy, 39, 42
Psychotic symptoms, 22, 23t
Psychotomimetic drugs, role of, in modeling schizophrenia, 18
Putamen, role in effect of antipsychotic drugs, 16, 17

Quality of life

factors in schizophrenia, 243
with SGADs vs conventional therapy, 244

Quetiapine

adverse effects, 79-82, 80t
as first-line therapy, by co-morbidity, 40-41t
chemical structure of, 55
comparative efficacy of, 94-97, 96t
comparative incidence of extrapyramidal side effects in, 98, 102, 104
comparative side effects of, 98, 99t, 100t
diabetic ketoacidosis in, 161
discontinuation rates, in CATIE, 179
dopamine receptor affinity of, 101
dosing information for, 56-57t, 78-79
effect of, on glucose homeostasis, 162
effect of, on QTc interval, 111
effect on cognition by, 237
factors affecting absorption, 228
history, 77
in adolescents and children with schizophrenia, 214, 215-216
in CAFE study, 97
in CATIE trial, 94, 153t
in combination therapy for treatment-resistant schizophrenia, 207t
in first-episode schizophrenia, 97
in SGAD therapy, 37t
in the elderly, 218
in treatment algorithm, 38
in treatment of aggressive behavior, 173
in treatment-resistant schizophrenia, 204
mechanism of action, 77
metabolism of, 229-233, 230t
pharmacokinetics, 79
profiles for receptor binding, 54
receptor affinity of, 95t
sedative effect, in clinical trials, 112
studies of, 77-78
vs risperidone in treatment-resistant schizophrenia, 201
weight gain with, 150, 151, 152t

Quinidine

contraindicated with ziprasidone, 89, 232
effect of, on metabolism of antipsychotic drugs, 231t

QTc changes, comparative incidence of, in SGADs, 100t

Raclopride, role of, in dopaminergic receptor-deficit hypothesis, 18

Rash

comparative incidence of, in SGAD therapy, 99t
with clozapine, 67t
with quetiapine, 80t
with risperidone, 84t
with ziprasidone, 88t

Rating scales, 42-48, 44-47t

Receptor affinities, of SGADs, 95t

Receptor antagonism, associated adverse effects of, 122t

Receptor-binding profile, of quetiapine, 93

Relapse

factors in, 241
rates, 241

Relationships, as factor in relapse, 241

Remission

Schizophrenic Working Group consensus on, 184, 185-186t
SGAD vs conventional therapy for, 185

Renal disease, in diagnosis of psychotic disorder, 30t

Renal insufficiency, in predisposition to QTc prolongation, 110

Renal metabolism

excretion by, 233
of paliperidone ER, 76

Repaglinide (Prandin), antidiabetic mechanism of, 164-165t

Residual type, in categorization of schizophrenia, 27

Respiratory tract infection

comparative incidence of, in SGAD therapy, 99t
with ziprasidone, 88t

Restlessness

in rebound phenomenon, 63
with clozapine, 66t

RGS4, in vulnerability for schizophrenia, 21t

Rheumatic fever, in predisposition to QTc prolongation, 110

Rhinitis

comparative incidence of, in SGAD therapy, 99t
with aripiprazole, 61t
with olanzapine therapy, 74-75t
with quetiapine, 80t
with risperidone, 84t
with ziprasidone, 88t

Rifampin, effect of, on metabolism of antipsychotic drugs, 231t

Rigidity

in Levenson's diagnostic criteria for NMS, 131t
with clozapine, 67t

Rimonabant, use of, in patients on antipsychotic drugs, 156

Risk factors, for development of schizophrenia, 20

Risperdal. See also *Risperidone*.

adverse effects, 83-86, 84t
dosing information for, 56-57t, 82-83
history, 82

Risperdal (*continued*)

- in management of acute psychosis, 170-171t
 - in SGAD therapy, 37t
 - long-acting
 - adverse effects of, 193-194
 - dosing guidelines for, 193
 - pharmacology and pharmacokinetics of long-acting preparations of, 191
 - preparation and use of, 194t
 - studies of, 195
 - mechanism of action, 82
 - pharmacokinetics, 83
- ### Risperidone
- adverse effects, 83-86, 84t
 - as first-line therapy, by co-morbidity, 40-41t
 - as first-line therapy in elderly patients, 218
 - with Parkinson's disease, Alzheimer's disease, 219
 - chemical structure of, 55
 - comparative efficacy of, 94-97, 96t
 - comparative incidence of extrapyramidal side effects in, 98, 102, 104
 - comparative side effects of, 98, 99t, 100t
 - diabetic ketoacidosis in, 161
 - discontinuation rates, in CATIE, 179
 - dopamine receptor affinity of, 101
 - dosing information for, 56-57t, 82-83
 - effect of, on glucose homeostasis, 162
 - effect of, on QTc interval, 111
 - effect on cognition by, 237
 - FDA approval of, in prevention of relapse, 178
 - history, 82
 - in adolescents and children with schizophrenia, 214
 - in CAFE study, 97
 - in CATIE trial, 94
 - in combination therapy for treatment-resistant schizophrenia, 206, 207t
 - in first-episode schizophrenia, 97
 - in management of acute psychosis, 170-171t
 - in pregnancy/lactation, 225
 - in schizophrenia with substance abuse, 221
 - in SGAD therapy, 37t
 - in treatment algorithm, 38
 - in treatment of aggressive behavior, 173
 - in treatment-resistant schizophrenia, 201, 204
 - vs haloperidol, 201
 - lipid changes with, 165
 - long-acting
 - adverse effects of, 193
 - dosing guidelines for, 193
 - pharmacology and pharmacokinetics of long-acting preparations of, 191
 - potential benefits of in young patients, 214, 215-216

Risperidone, long-acting (*continued*)

- preparation and use of, 194t
 - studies of, 195
 - mechanism of action, 82
 - metabolism of, 229-233, 230t
 - pharmacokinetics, 83
 - potential benefits of new forms of, 182
 - potential cost benefits of, 246
 - profiles for receptor binding, 54
 - receptor affinity of, 95t
 - relapse with, vs conventional therapy, 242
 - remission rates with, 185
 - sedative effect, in clinical trials, 112
 - studies of, 82
 - vs haloperidol, 82
 - Marder and Meibach, US-Canada joint, 82
 - weight gain with, 150, 151, 152t
 - in CATIE trial, 153t
 - Rivastigmine, potential benefits of, in schizophrenia, 239
 - Romano-Ward syndrome, in predisposition to QTc prolongation, 110
 - Rosiglitazone (Avandia), antidiabetic mechanism of, 164-165t
- ### Salivation
- with clozapine, 66t
 - with risperidone, 84t
- SAS See *Simpson-Angus Scale*.
- ### Schizoaffective disorder
- exclusion of, in diagnosis of schizophrenia, 29t
 - in diagnosis of psychotic disorder, 30t
 - SGAD therapy in, 222-223
 - treatment of, with antipsychotic drugs, 33
- ### Schizophrenia
- defined, *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition, 26
 - treatment of, with antipsychotic drugs, 33
- ### Schizophrenic Working Group, consensus on remission, 184, 185-186t
- ### Second-generation antipsychotic drugs (SGADs). See also specific drugs.
- available agents for, 37t
 - chemical structure of, 55
 - comparative side effects of, 98, 99t
 - depot preparations of, 191-195
 - distinction vs conventional therapy, 34, 96-97
 - dosing information for, 56-57t
 - effect of receptor affinity with weight gain in, 149
 - effect on cognition by, 237
 - factors affecting absorption, 227-228
 - future directions in, 249
 - in adolescents and children with schizophrenia, 214
 - in management of acute psychosis, 170-171t
 - in management of aggressive behavior, 172-173

SGADs (*continued*)

- in pregnancy/lactation, 225
- in prevention of relapse, 178
- in schizoaffective disorder, 222
- in the elderly, 217-220
- in therapy for treatment-resistant schizophrenia, 198, 199, 200-208
- in treatment algorithm, 38
- incidence of extrapyramidal effects with, vs conventional therapy, 98, 102
- introduced for antipsychotic use, 33-34
- mechanism of action, 53
- metabolism and distribution of, 229-233, 230t
- potential benefits of, 31
- profiles for receptor binding, 54
- risk of diabetes with, 159
- serotonin-to-dopamine binding ratios of, 19
- vs conventional therapy in treatment adherence, 242-243
- vs conventional treatment of psychiatric emergencies, 168

Sedation

- by receptor antagonism, 122, 122t
- comparative incidence of, in SGAD therapy, 99t
- comparative incidence of, in SGADs, 100t
- comparative, with conventional antipsychotic therapy, 122, 123t
- in CATIE trial, 112
- in sexual dysfunction, 106t
- with clozapine, 67, 67t

Seizures

- comparative incidence of, in SGADs, 100t
- in treatment with conventional antipsychotics, 125
- preventative measures for, 70
- with clozapine, 67t, 69-70
- with ziprasidone, 90

Self-care, in symptomatology of schizophrenia, 25

Serentil. See also *Mesoridazine*.

- in conventional antipsychotic therapy, 36t

Seroquel. See also *Quetiapine*.

- adverse effects, 79-82, 80t
- dosing information for, 56-57t, 78-79
- history, 77
- in SGAD therapy, 37t
- mechanism of action, 77
- pharmacokinetics, 79
- studies of, 77-78

Serotonin hypothesis of psychosis, 19

Serotonin receptor antagonism

- adverse effects of, 122t
- effect of, on satiety, 148
- in management of aggressive behavior, 172
- in sexual dysfunction, 106t
- role of, in schizophrenia, 19

Serotonin receptor binding, role of, in antipsychotic drug activity, 19, 53

Sertindole

- in new developments for treating schizophrenia, 250
- weight gain with, 151

Sertraline

- effect of, on metabolism of antipsychotic drugs, 231t
- in schizoaffective disorder, 223
- in schizophrenia with depression, 223

Sexual dysfunction

- treatment options for, 109t
- with antipsychotic therapy, 129
- in CATIE study, 108
- in SGAD therapy, 107-109
- mechanism of, in antipsychotic therapy, 103, 106, 106t
- treatment considerations in, 40-41t

SGADs. See *Second-generation antipsychotic drugs*.

Sibutramine, use of, in patients on antipsychotic drugs, 155

Sildenafil, in treatment of sexual disturbance in antipsychotic therapy, 109t

Simpson-Angus Scale (SAS), in evaluation of antipsychotic side effects, 48, 49

Single photon emission computed tomography (SPECT), in characterization of brain abnormality, 14

Sinusitis, with risperidone, 84t

Sleep disturbance

- in symptomatology of schizophrenia, 25
- with clozapine, 66t

Social aptitude, impairment of, 25t

Social dysfunction

- cognitive impairment with, 235
- in differential diagnosis, 28t

Social skills training (SST), in psychosocial rehabilitation, 42

Somatic delusions, defined, 23t

Somatic disturbance, in assessment of psychopathology, 44t

Somnolence

- in antipsychotic-treated children, 215
- with aripiprazole, 61t
- with long-acting risperidone, 193-194
- with olanzapine therapy, 74-75t
- with paliperidone ER, 78t
- with quetiapine, 80t
- with risperidone, 84t
- with ziprasidone, 88t

Sotalol, contraindicated with ziprasidone, 89, 232

Sparfloxacin, contraindicated with ziprasidone, 89

SPECT. See *Single photon emission computed tomography*.

SST. See *Social skills training*.

Stabilization therapy. See *Maintenance therapy*.

Starlix. See *Nateglinide*.

- antidiabetic mechanism of, 164-165t

Stelazine. See also *Trifluoperazine*.
in conventional antipsychotic therapy, 36t

Strauss, characterization of schizophrenia by, 21

Structural abnormality, 15t

Substance abuse
as factor in relapse, 241
with schizophrenia, treatment of, 220-222

Substantia nigra, role in effect of antipsychotic drugs, 16, 17

Sugar-free gum, in hypersalivation, 68t

Suicidal tendency, treatment considerations in, 40-41t

Suicide
incidence of, in schizophrenia, 173
increased risk, with conventional therapy, 174
risk factors for, 174, 175t
risk of, 27

Sulfonylureas, antidiabetic mechanism of, 164-165t

Superior temporal cortex, role in effect of antipsychotic drugs, 16, 17

Suspiciousness, in assessment of psychopathology, 46t

Sweating
comparative incidence of, in SGAD therapy, 99t
with clozapine, 66t

Switching drug therapies
benefits of, in SGAD therapy, 179
rationale for, 178-179
strategies for, 180t

Symptoms of schizophrenia, 13, 25, 25t
responsiveness to treatment, 31

Syncope
comparative incidence of, in SGAD therapy, 99t
with clozapine, 66t
with olanzapine, 73

Tachycardia
comparative incidence of, in SGAD therapy, 99t
in Levenson's diagnostic criteria for NMS, 131t
with clozapine, 66t, 69
with olanzapine, 73, 74-75t
with paliperidone ER, 77, 78t
with quetiapine, 80t
with risperidone, 84t
with ziprasidone, 88t

Tangentiality, in thought disorder, 24t

Tardive dyskinesia
in schizophrenia with substance abuse, 220-222
in sexual dysfunction, 106t
susceptibility to, of elderly patients, 218
treatment considerations in, 40-41t

Tegmentum, role in effect of antipsychotic drugs, 16, 17

Temporal cortex, impact of functional changes in, 16t

Tension, in assessment of psychopathology, 45t

Terazosin, in hypersalivation, 68t

Texas Implementation of Medication Algorithm, 38
guidelines for combination therapy in treatment-resistant schizophrenia, 206, 207t

Texas Medication Algorithm Project (TMAP)
treatment algorithm from, 38
treatment recommendations of, 35, 38

Thiazolidinediones, antidiabetic mechanism of, 164-165t

Thioridazine
adverse effects with, 123t
anticholinergic effects of, 125
chemical structure of, 118-119
contraindicated with ziprasidone, 89, 232
dopamine receptor affinity of, 101
dosing guidelines for, 120-121t
effect of, on QTc interval, 111
effect on cognition by, 237
in conventional antipsychotic therapy, 36t
introduced for antipsychotic use, 33
metabolism, 230t
orthostatic hypotension with, 124
weight gain with, 149, 151

Thiothixene
adverse effects with, 123t
chemical structure of, 118-119
dosing guidelines for, 120-121t
in conventional antipsychotic therapy, 36t
introduced for antipsychotic use, 33

Thioxanthenes
as subclass of antipsychotic medication, 116, 118-119
chemical structure of, 118-119

Thorazine. See also *Chlorpromazine*.
in conventional antipsychotic therapy, 36t

Thought blocking

Thought broadcasting, defined, 23t

Thought disorder
characteristics of, 22, 24t
in assessment of psychopathology, 47t
with functional brain changes, 16t

Thought insertion, defined, 23t

TIMA. See *Texas Implementation of Medication Algorithm*.

TMAP. See *Texas Medication Algorithm Project*.

Toothache, with risperidone, 84t

Topiramate
in combination therapy for treatment-resistant schizophrenia, 207t
use of, in patients on antipsychotic drugs, 155

Torsades de pointes
with clozapine therapy, 69
with thioridazine, 124

Traditional antipsychotic drugs. See *Conventional therapy*.

- Transaminase elevations
 with olanzapine, 73
 with quetiapine, 81
- Transmitter disturbance, role of, in schizophrenia, 18-19
- Treatment goals, 35, 39
- Treatment options. See also *Conventional therapy, Second-generation antipsychotic drugs*.
 guidelines of the American Psychiatric Association, 35
 guidelines of the TMAP, 35
 historical approach, 33-34
- Treatment-resistant schizophrenia
 clozapine in, 197
 combination therapy for, 205-208
 criteria for diagnosis of, 198-199, 199t
 management guidelines for, 210-211t
 monotherapy for, 200-205
 vs chronicity, 197-198
- Tremor
 with aripiprazole, 61t
 with clozapine, 66t
 with olanzapine therapy, 74-75t
- Tricyclic antidepressants
 association with aggressive behavior, 172t
 effect of, on metabolism of antipsychotic drugs, 231t
- Trifluoperazine
 adverse effects with, 123t
 anticholinergic effects of, 125
 dosing guidelines for, 120-121t
 in conventional antipsychotic therapy, 36t
- Trilafon. See also *Perphenazine*.
 in conventional antipsychotic therapy, 36t
- Tuberoinfundibular tract
 effect of antipsychotic drugs on, 18
 role in effect of antipsychotic drugs, 16, 17
- Uncooperativeness, in assessment of psychopathology, 47t
- Undifferentiated type, in categorization of schizophrenia, 27
- Upper respiratory infection, with risperidone, 84t
- Urecholine. See *Bethanechol*.
- Urinary incontinence
 with clozapine, 67t, 71
 with olanzapine therapy, 74-75t
- Urinary tract infection, with olanzapine therapy, 74-75t
- V-AKT murine thymoma viral oncogene homolog 1, in vulnerability for schizophrenia, 21t
- Valproate
 in combination therapy for treatment-resistant schizophrenia, 207t
 in prevention of seizure with clozapine therapy, 70
 in schizoaffective disorder, 223
 in schizophrenia with depression, 223
- Vascular dementia, psychotic symptoms with, in the elderly, 217
- Vasoconstriction
 management of, 124
 with conventional therapies, 124
- Ventricular dilation, associated with schizophrenia, 15t
- Ventricular function, effects of antipsychotic drugs on, 109-110, 111t
- VEOS. See *Very-early-onset schizophrenia*.
- Verapamil, effect of, on metabolism of antipsychotic drugs, 231t
- Vertigo, comparative incidence of, in SGAD therapy, 99t
- Very-early-onset schizophrenia, 214
- Visual disturbance
 comparative incidence of, in SGAD therapy, 99t
 with clozapine, 66t
 with risperidone, 84t
- Vocational support
 in psychosocial rehabilitation, 42
- Vomiting
 with aripiprazole, 61t
 with clozapine, 67t
 with olanzapine therapy, 74-75t
 with risperidone, 84t
- Weight gain
 clinical consequences of, 147t
 comparative incidence of, in SGAD therapy, 99t, 100t
 in antipsychotic-treated children, 215
 in sexual dysfunction, 106t
 management of, in treated patients, 152-156, 154t
 mechanism of, 148-149
 minimal with paliperidone ER, 76
 with antipsychotic medications, 149-152, 150, 151, 153t
 with antipsychotic therapy, 128
 with clozapine, 66t, 70
 with long-acting risperidone, 193-194
 with olanzapine, 73, 74-74t
 with quetiapine, 80t, 81
 with risperidone, 85-86
- Word salad, defined, in thought disorder, 24t
- Xenical. See *Orlistat*.
- Xerolube, in treatment of anticholinergic effects of conventional antipsychotics, 125
- Ziprasidone
 adverse effects, 87-90, 88t
 as first-line therapy, by co-morbidity, 40-41t
 chemical structure of, 55
 comparative efficacy of, 94-97, 96t
 comparative incidence of extrapyramidal side effects in, 98, 102, 104
 comparative side effects of, 98, 99t, 100t

Ziprasidone (*continued*)

- discontinuation rates, in CATIE, 179
- dopamine receptor affinity of, 101
- dosing information for, 56-57t, 87
- drug interactions, contraindications with, 232-233, 232t
- effect of, on glucose homeostasis, 162
- effect of, on QTc interval, 110-112, 111
- effect on cognition by, 237
- efficacy, 86-87
- factors affecting absorption, 228
- history, 86
- in adolescents and children with schizophrenia, 214, 215-216
- in CATIE trial, 94
- in combination therapy for treatment-resistant schizophrenia, 207t
- in long-term maintenance therapy, 178
- in management of acute psychosis, 170-171t
- in SGAD therapy, 37t
- in treatment algorithm, 38
- in treatment-resistant schizophrenia, 204
- in young patients, 97
- lipid changes with, 165
- mechanism of action, 86
- metabolism of, 229-233, 230t, 233
- pharmacokinetics, 87
- profiles for receptor binding, 54
- receptor affinity of, 95t
- sedative effect, in CATIE trial, 112
- weight gain with, 150, 151, 152t
 - in CATIE trial, 153t

Zotepine, in new developments for treating schizophrenia, 250

Zyprexa. See also *Olanzapine*.

- adverse effects of, 73, 74t
- dosing information for, 56-57t, 72
- efficacy, 71
- history of, 71
- in management of acute psychosis, 170-171t
- in SGAD therapy, 37t
- mechanism of action, 71
- pharmacokinetics, 72
- vs haloperidol, 71-72
- studies of, 86-87
 - vs haloperidol, 87